FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL							
OMB Number:	3235- 0104						
Estimated average burden							
hours per response:	0.5						

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF **SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* IMRAN MIR A			Requi (Mont	2. Date of Event Requiring Statement (Month/Day/Year) 07/29/2021 3. Issuer Name and Ticker or Trading Symbol Rani Therapeutics Holdings, Inc. [RANI]							
(Last) (First) (Middle) C/O RANI THERAPEUTICS LLC 2051 RINGWOOD AVE. (Street)			0/2021	Issuer (Check all applicable X Director	(Check all applicable) X Director Officer (give		ng Person(s) to 10% Owner Other (specify below)		If Amendment, Date of Original Filed (Month/Day/Year) 07/29/2021 Individual or Joint/Group Filing (Check Applicable Line)		
SAN JOSE		95131	_							Person	by More than One Person
(City)	(State)	(Zip)									
Table I - Non-Derivative Securities Beneficially Owned											
1. Title of Security (Instr. 4)			Amount of Securit Beneficially Owned (4)				4. Nature of Indirect Beneficial Ownership (Instr. 5)				
Class A Common Stock				829,435(1)	829,435 ⁽¹⁾ I			See footnote ⁽¹⁾⁽²⁾			
Class B Common Stock				24,954,843(1	I			See footnote ⁽¹⁾⁽³⁾			
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)											
1. Title of Deri			s. Title and Amount of Securities Inderlying Derivative Security (Instr. I)			4. Conversion or Exercise Price of		5. Ownership Form:	6. Nature of Indirect Beneficial Ownership (Instr.		
			Date Exercisable	Expiration Date	Title	Amour Numbe Shares	nt or Derivater of Securit		ive or Indirect		5)
Class A Corr	ımon LLC U	nits ⁽⁴⁾	(4)	(4)	Class A Common Stock ⁽⁴⁾	24,954,843(1)		(4)		I	See footnote ⁽¹⁾⁽³⁾

Explanation of Responses:

- 1. This amendment is being filed to correctly reflect the shares held indirectly.
- 2. Represents 378,533 shares of Class A Common Stock of the Issuer ("Class A Shares") held by Biologix Partners, LP and 450,902 Class A Shares held by VH Rani, LP. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
- 3. Represents 22,389,982 shares of Class B Common Stock of the Issuer ("Class B Shares") held by InCube Labs, L.L.C., 2,492,441 Class B Shares held by InCube Ventures II, L.P. and 72,420 Class B Shares held by Rani Investment Corp. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
- 4. Represents Common LLC Units of Rani Therapeutics, LLC, a direct subsidiary of the Issuer. The Common LLC Units are redeemable at the election of the Reporting Person at any time for newly-issued Class A Shares on a one-for-one basis or, if mutually agreed with the Issuer, a cash payment equal to the volume weighted average market price of one Class A Share for each Common LLC Unit redeemed (subject to customary adjustments, including for stock splits, stock dividends and reclassifications). However, the Issuer may elect to effect a direct exchange of such Class A Shares (or such cash, if mutually agreed) for such Common LLC Units.

Remarks:

/s/ Josh Seidenfeld,

Attorney-in-Fact for Mir 08/02/2021

Imran

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.